953 related articles for article (PubMed ID: 16398057)
1. Vascular effects of calcium channel antagonists: new evidence.
Richard S
Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
[TBL] [Abstract][Full Text] [Related]
2. Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension.
Hayashi K; Ozawa Y; Fujiwara K; Wakino S; Kumagai H; Saruta T
Am J Nephrol; 2003; 23(4):229-44. PubMed ID: 12840599
[TBL] [Abstract][Full Text] [Related]
3. Ca2+ channel subtypes and pharmacology in the kidney.
Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
[TBL] [Abstract][Full Text] [Related]
4. [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?].
Richard S; Virsolvy A; Fort A
Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):166-73. PubMed ID: 18565491
[TBL] [Abstract][Full Text] [Related]
5. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney.
Ozawa Y; Hayashi K; Nagahama T; Fujiwara K; Saruta T
Hypertension; 2001 Sep; 38(3):343-7. PubMed ID: 11566902
[TBL] [Abstract][Full Text] [Related]
6. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
[TBL] [Abstract][Full Text] [Related]
7. Functional and pharmacological consequences of the distribution of voltage-gated calcium channels in the renal blood vessels.
Hansen PB
Acta Physiol (Oxf); 2013 Apr; 207(4):690-9. PubMed ID: 23351056
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels.
Hansen PB; Jensen BL; Andreasen D; Skøtt O
Circ Res; 2001 Sep; 89(7):630-8. PubMed ID: 11577029
[TBL] [Abstract][Full Text] [Related]
9. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo.
Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Takamatsu I; Ozawa Y; Saruta T
J Hypertens; 2001 Nov; 19(11):2031-7. PubMed ID: 11677369
[TBL] [Abstract][Full Text] [Related]
10. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.
Furukawa T; Nukada T; Namiki Y; Miyashita Y; Hatsuno K; Ueno Y; Yamakawa T; Isshiki T
Eur J Pharmacol; 2009 Jun; 613(1-3):100-7. PubMed ID: 19401195
[TBL] [Abstract][Full Text] [Related]
11. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.
Tanaka H; Shigenobu K
Cardiovasc Drug Rev; 2002; 20(1):81-92. PubMed ID: 12070536
[TBL] [Abstract][Full Text] [Related]
12. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes.
Furukawa T; Nukada T; Miura R; Ooga K; Honda M; Watanabe S; Koganesawa S; Isshiki T
J Cardiovasc Pharmacol; 2005 Mar; 45(3):241-6. PubMed ID: 15725949
[TBL] [Abstract][Full Text] [Related]
13. T-type calcium channels in the regulation of afferent and efferent arterioles in rats.
Feng MG; Li M; Navar LG
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F331-7. PubMed ID: 14583435
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation.
Hayashi K; Wakino S; Homma K; Sugano N; Saruta T
J Pharmacol Sci; 2005 Nov; 99(3):221-7. PubMed ID: 16293936
[TBL] [Abstract][Full Text] [Related]
15. Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR
Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
[TBL] [Abstract][Full Text] [Related]
16. Relative contributions of Ca2+ mobilization and influx in renal arteriolar contractile responses to arginine vasopressin.
Fallet RW; Ikenaga H; Bast JP; Carmines PK
Am J Physiol Renal Physiol; 2005 Mar; 288(3):F545-51. PubMed ID: 15536171
[TBL] [Abstract][Full Text] [Related]
17. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
Moore KH; Clemmer JS
Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
[TBL] [Abstract][Full Text] [Related]
18. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.
Perez-Reyes E; Van Deusen AL; Vitko I
J Pharmacol Exp Ther; 2009 Feb; 328(2):621-7. PubMed ID: 18974361
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension.
Tomino Y
Curr Hypertens Rev; 2013 May; 9(2):108-14. PubMed ID: 23971692
[TBL] [Abstract][Full Text] [Related]
20. Functional importance of L- and P/Q-type voltage-gated calcium channels in human renal vasculature.
Hansen PB; Poulsen CB; Walter S; Marcussen N; Cribbs LL; Skøtt O; Jensen BL
Hypertension; 2011 Sep; 58(3):464-70. PubMed ID: 21788606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
